Yang Xu, Meng Qifang, Wu Pingyu
Department of Endocrinology, Jiashan Second People's Hospital, Jiaxing, Zhejiang, China.
Med Sci Monit. 2025 Jun 16;31:e947157. doi: 10.12659/MSM.947157.
BACKGROUND The rising comorbidity of T2DM and MASLD, driven by insulin resistance (IR), underscores the need for effective interventions. This study evaluated the impact of a 3-month structured lifestyle intervention on hepatic steatosis, IR, and metabolic parameters in patients with T2DM-MASLD. MATERIAL AND METHODS Thirty-seven patients received personalized low-calorie diets and exercise regimens. Hepatic fat was quantified via MRI-PDFF, with biochemical parameters and HOMA-IR assessed at baseline and after intervention. Participants were stratified into compliant (³5% weight loss, n=26) and non-compliant groups (<5%, n=11). RESULTS Both groups had significant reductions in BMI and hepatic fat fraction (p<0.05), with greater improvements in the compliant group. The compliant group had significant improvements in TBIL, AST, ALT, HDL-c, and HOMA-IR (a significant 31.2% reduction in HOMA-IR [p<0.001]). Multivariate analysis revealed that MRI-PDFF explained 42.5% of hepatic fat variability. CONCLUSIONS A 5% weight loss threshold effectively ameliorates hepatic steatosis and IR, reinforcing lifestyle modification as a cornerstone in T2DM-MASLD management. Integration of digital monitoring tools enhances compliance, addressing a critical barrier in real-world implementation.
由胰岛素抵抗(IR)驱动的2型糖尿病(T2DM)和代谢功能障碍相关脂肪性肝病(MASLD)合并症的增加,凸显了有效干预措施的必要性。本研究评估了为期3个月的结构化生活方式干预对T2DM-MASLD患者肝脂肪变性、IR和代谢参数的影响。
37例患者接受个性化低热量饮食和运动方案。通过磁共振成像-质子密度脂肪分数(MRI-PDFF)对肝脏脂肪进行定量,在基线和干预后评估生化参数和稳态模型评估的胰岛素抵抗(HOMA-IR)。参与者被分为依从组(体重减轻³5%,n=26)和非依从组(<5%,n=11)。
两组的体重指数(BMI)和肝脏脂肪分数均显著降低(p<0.05),依从组改善更明显。依从组的总胆红素(TBIL)、谷草转氨酶(AST)、谷丙转氨酶(ALT)、高密度脂蛋白胆固醇(HDL-c)和HOMA-IR均有显著改善(HOMA-IR显著降低31.2%[p<0.001])。多变量分析显示,MRI-PDFF解释了42.5%的肝脏脂肪变异性。
5%的体重减轻阈值可有效改善肝脂肪变性和IR,强化生活方式改变作为T2DM-MASLD管理的基石。整合数字监测工具可提高依从性,解决实际应用中的关键障碍。